Craniorachischisis is the most severe kind of neural tube defect (NTD). In this condition, the skull and brain do not form and close properly (anencephaly), and the spinal canal also stays open along a long segment of the back (rachischisis). Because both the head and spine are open, the baby’s brain and spinal cord are exposed. This defect happens very early in pregnancy, around the third to fourth week after conception, when the neural tube is supposed to fold and close. Craniorachischisis is usually fatal before or shortly after birth. Orpha+2CDC Archive+2
Craniorachischisis is the most severe neural tube defect (NTD). In this condition, the top of the skull and brain do not form properly (anencephaly) and the spine stays open along a long segment (rachischisis). The baby’s brain and spinal cord are exposed and cannot develop normally. Sadly, this condition is lethal; most affected pregnancies end in miscarriage or stillbirth, and liveborn infants survive only hours to days. Orpha+2Radiopaedia+2
Very early in pregnancy (weeks 3–4), the flat neural plate must roll up and close like a zipper to form the neural tube, which later becomes the brain and spinal cord. If the front/top closure and the spinal closure fail right at the start, the result is craniorachischisis. Research shows this failure involves problems in the cell-orientation system called planar cell polarity (PCP)—genes such as CELSR1 and SCRIB can be involved—together with nutrition and environment. Folate pathways and heat or drug exposures can add risk. PMC+2PMC+2
Doctors consider craniorachischisis an “open” NTD, meaning the nervous tissue is not covered by skin or bone. It combines two major defects—anencephaly and spina bifida/rachischisis—into one continuous opening from the head down the spine. Genetic Diseases Info Center+1
Other names
Doctors and radiologists may use several names for the same condition. Common alternatives include: “craniorachischisis totalis,” “craniospinal rachischisis,” “anencephaly with total open spina bifida,” and “open craniospinal neural tube defect.” All of these mean there is an open defect of the skull/brain plus a long open defect of the spine. Radiopaedia+1
Types
Craniorachischisis can be described by how much of the spine is involved:
Totalis: the open defect involves the head and essentially the entire spine. This is the classic and most severe type. Radiopaedia
Partial craniorachischisis: the defect involves the head and a long—but not complete—segment of the spine (for example, the cervical or upper thoracic spine). Some public-health manuals note that, when only the upper spine is involved, it can look similar to “holoanencephaly.” CDC Archive
Very early in embryo development, a flat layer of cells must roll up and fuse to form a tube (the neural tube). If this closure fails at the head end and then along the back, craniorachischisis results. Multiple influences can disturb closure—gene changes, low folate status, certain medicines, high fever/heat exposure, diabetes, and more. Closure also depends on a tissue “polarity” system called planar cell polarity (PCP); mutations in PCP genes like CELSR1, SCRIB, and VANGL have been linked to craniorachischisis. PMC+2PMC+2
Causes and risk factors
Low folate (folic acid) intake before and very early in pregnancy. Folate supports DNA and cell division; lack of it raises NTD risk. This is why 400 mcg folic acid daily is recommended for anyone who could become pregnant. CDC+1
No folic-acid supplement before conception. Neural tube closure occurs before many people know they are pregnant; starting folic acid before conception lowers risk. CDC
Previous pregnancy affected by an NTD. Recurrence risk is higher; higher folic acid dosing is often advised pre-conception. Prenatal Catalog
Maternal diabetes. High glucose and oxidative stress in early embryonic life increase NTD risk. ScienceDirect
Maternal obesity. Obesity roughly doubles NTD risk even when supplements are used. IMR Press
Exposure to valproic acid (sodium valproate) in early pregnancy. This antiseizure/mood-stabilizing drug is strongly linked to NTDs and other malformations. PMC+1
Other folate-antagonist medicines (e.g., high-dose methotrexate, some antimetabolites). These can interfere with folate pathways. (General NTD risk evidence.) PMC
Maternal hyperthermia (fever or heat exposure) early in pregnancy. Elevated temperature during the critical weeks is associated with NTDs. PMC+1
Genetic variants in folate-metabolism genes (e.g., MTHFR C677T). Some meta-analyses suggest increased NTD risk, although effect size and generalizability vary. PubMed+1
Mutations in planar cell polarity genes (e.g., CELSR1, SCRIB, VANGL1/2). These disrupt the cell movements needed for tube closure and are directly linked to craniorachischisis in human studies and animal models. PMC+1
Low health-service access or late antenatal care. Late care can delay folate advice and risk-reduction steps. PMC
Nutrition patterns with low folate-fortified foods. Lack of folic-acid–fortified staples increases population risk. CDC
Unplanned pregnancy without preconception supplementation. Because closure is so early, missing the pre-conception window matters. CDC
Certain environmental exposures (solvents, pesticides) suggested in studies. Evidence is mixed; overall message is to minimize toxic exposures when planning pregnancy. PMC
Zinc or other micronutrient insufficiency (less established than folate). Some reviews group micronutrient deficits with nutrition-related risks. PMC
Family history of NTDs. Multifactorial inheritance raises baseline risk in families. PMC
Certain infections with fever early in gestation. The fever itself (hyperthermia) is the likely risk driver. PMC
Teratogenic drug combinations or high doses. Besides valproate, using multiple teratogens raises concern. (General principle summarized in reviews.) PMC
Very low socioeconomic resources. Associated with reduced access to supplements and healthcare. PMC
Unknown factors. Even with modern science, many cases have no single identifiable cause; most are multifactorial. PMC
Symptoms / clinical features
Because craniorachischisis is a structural defect in the fetus, “symptoms” are mostly features seen on scans or at delivery, plus pregnancy findings:
Absence of the cranial vault and exposed brain tissue (anencephaly). This is the hallmark head finding. CDC Archive
A long, open spinal groove with exposed neural tissue (rachischisis). CDC Archive
Continuous defect from head down the spine (cranial plus spinal opening). Orpha
Very early ultrasound signs such as acrania/exencephaly in the first trimester (11–14 weeks). PMC+1
“Mickey Mouse” / “beret” ultrasound signs that help recognize the acrania–exencephaly–anencephaly sequence early. Radiopaedia+2PMC+2
Markedly elevated maternal serum alpha-fetoprotein (AFP) in open NTDs. GIM Journal
Positive acetylcholinesterase (AChE) in amniotic fluid when tested—supports an open NTD. Mayo Clinic Laboratories+1
Polyhydramnios (too much amniotic fluid) may be present with severe cranial defects. (Common with anencephaly; supports suspicion.) PMC
Reduced or abnormal fetal movements late in pregnancy (nonspecific but can occur with severe CNS anomalies). PMC
Incompatibility with life—most fetuses miscarry, are stillborn, or die soon after birth. Genetic Diseases Info Center
If liveborn, lack of consciousness and absent cranial reflexes due to missing cerebral structures. (Consistent with anencephaly physiology.) PMC
Visible open spinal lesion on newborn exam when delivery occurs. CDC Archive
Associated body-wall and limb anomalies in some cases (important for differential diagnosis). Fetal MRI helps sort these out. ScienceDirect
Shortened calvarial/cranial pole on scan with irregular cranial surface (exencephaly/anencephaly sequence). ScienceDirect
Fetal demise due to the severity of the central nervous system defect. PMC
Diagnostic tests
A) Physical exam (after delivery or termination)
Newborn or fetal physical examination. Confirms absence of cranial vault, exposed brain tissue, and open spinal groove. This direct observation establishes the diagnosis when imaging is unavailable. Clinical Images Journal
Measurement and documentation of the spinal defect length. Helps record the extent (total vs partial). CDC Archive
Systematic exam for other anomalies (limb, body wall). Guides counseling and rules out limb-body wall complex or amniotic band sequence. ScienceDirect
Placental and cord exam. Looks for signs of infection or disruption that could accompany severe anomalies. (General perinatal pathology practice.) PMC
B) Manual / bedside clinical tests
Fundal-height tracking. Disproportionate growth can hint at polyhydramnios from severe CNS defects, prompting targeted imaging. PMC
Bedside neurologic reflex checks in rare liveborns. Profound absence of higher-brain reflexes is expected in anencephaly. PMC
Head/cranial palpation (post-delivery). Confirms absent skull bones (acrania/anencephaly). CDC Archive
Bedside counseling checklist. While not a “test,” structured counseling is a recommended step once a lethal anomaly is identified. PMC
C) Laboratory and pathological tests
Maternal serum alpha-fetoprotein (AFP) screening. High AFP in the second trimester suggests an open NTD and triggers targeted ultrasound. GIM Journal
Amniotic-fluid AFP. Elevated values confirm an open defect when ultrasound shows suspicious findings. PubMed
Amniotic-fluid acetylcholinesterase (AChE). Presence of AChE strongly supports an open NTD like craniorachischisis; blood contamination can cause false positives, so the lab interprets with care. Mayo Clinic Laboratories
Genetic testing (karyotype/microarray ± gene panels). Looks for chromosomal changes or pathogenic variants (including PCP pathway genes) to inform recurrence risk counseling. The ObG Project
Perinatal autopsy (gross and histology). Provides definitive documentation of the cranial and spinal defects and any associated malformations. Clinical Images Journal
Maternal metabolic labs (e.g., diabetes screening). Identify modifiable maternal conditions linked to NTD risk. ScienceDirect
D) Electrodiagnostic tests
EEG (if a liveborn survives briefly). Typically shows no cortical activity because cortical tissue is absent; rarely used but explains prognosis. (Physiologic expectation with anencephaly.) PMC
Brainstem auditory evoked responses (BAER) in research/rare cases. Often absent or severely abnormal; seldom performed clinically in this context. (Neurophysiology principle in anencephaly.) PMC
Fetal heart rate monitoring (CTG) during labor. Not a diagnostic test for the anomaly itself, but part of routine intrapartum care if pregnancy continues. Medscape
E) Imaging tests
First-trimester obstetric ultrasound (11–14 weeks). Key test: detects acrania/exencephaly early and can show the open spinal canal; enables timely, compassionate counseling. PMC+1
Second-trimester detailed ultrasound (anatomy scan). Confirms anencephaly, shows long open spine (rachischisis), and looks for associated anomalies. Radiopaedia
3D ultrasound (as available). Helps visualize the cranial vault absence and the extent of spinal opening for documentation and counseling. Radiopaedia
Fetal MRI. Useful when ultrasound needs clarification or to distinguish craniorachischisis from other complex body-wall syndromes. MRI is adjunctive, not a routine screening tool. PMC+1
Targeted ultrasound markers (e.g., “Mickey Mouse” / “beret” signs). These pattern-based signs support early recognition of the acrania-exencephaly-anencephaly sequence. PMC+1
Post-delivery “babygram” X-ray. May document absent cranial bones and vertebral defects; pathology remains the gold standard. PMC
Follow-up imaging in subsequent pregnancies. Early first-trimester scans are advised to reassure or detect recurrence early. (Practice recommended in NTD guidelines.) PubMed
Non-pharmacological treatments (therapies & supports)
Because craniorachischisis is not treatable, these focus on prevention, early detection, counseling, and palliative support. Each item includes purpose and mechanism in simple terms.
Daily folic-acid education before pregnancy. Purpose: lower NTD risk. Mechanism: raises folate levels needed for neural tube closure. All who could become pregnant should take 400–800 mcg/day. USPSTF
High-risk folic-acid counseling. Purpose: reduce recurrence risk after a prior NTD or in high-risk situations. Mechanism: higher doses (often 4–5 mg/day) started ≥1 month before conception through early pregnancy. MGH Women’s Mental Health
Preconception clinic visit. Purpose: review medical conditions, medications, and nutrition. Mechanism: addresses risks (diabetes control, ASM changes) before neural tube closure. PMC+1
Medication review (avoid valproate where possible). Purpose: lower teratogenic risk. Mechanism: switch to safer ASMs (e.g., lamotrigine/levetiracetam) under specialist care. JAMA Network
Fever/heat avoidance education. Purpose: reduce hyperthermia risk. Mechanism: treat fevers promptly; avoid hot tubs/saunas early in pregnancy. Lippincott Journals
Nutrition coaching. Purpose: ensure adequate folate, B12, choline, zinc. Mechanism: diet rich in leafy greens, fortified grains, animal-source B12, eggs/legumes for choline. CDC+2PMC+2
Diabetes optimization before conception. Purpose: reduce NTD risk. Mechanism: tight glucose control; multidisciplinary care. PMC
Weight management support. Purpose: address obesity-related risk. Mechanism: healthy eating and activity before pregnancy. PMC
Folic-acid food fortification (public-health). Purpose: population-level prevention. Mechanism: raises baseline folate intake and lowers NTD rates. PMC
Early first-trimester ultrasound access. Purpose: earlier, clearer diagnosis. Mechanism: detects acrania/exencephaly/anencephaly at 11–14 weeks. PMC
Informed decision-making counseling. Purpose: support choices within local law (continuation vs termination). Mechanism: structured conversations with MFM, neonatology, ethics. Pediatric Ethicscope
Perinatal palliative care planning. Purpose: comfort-focused birth/after-birth plan. Mechanism: symptom relief, memory-making, family support. PubMed
Bereavement support and follow-up. Purpose: mental health after loss. Mechanism: grief counseling, support groups, social work. perinatalhospice
Pathology examination (with consent). Purpose: confirm diagnosis; inform recurrence counseling. Mechanism: detailed post-delivery exam. CDC Archive
Genetic counseling. Purpose: discuss recurrence risks and testing options for future pregnancies. Mechanism: review family history and possible variants (e.g., PCP genes). PMC
Interpregnancy planning. Purpose: start folic acid well before trying again. Mechanism: ensure supplements ≥1 month pre-conception. USPSTF
Public education on unplanned pregnancy and folate. Purpose: reach people before they know they’re pregnant. Mechanism: promote daily 400 mcg folic acid for all who could become pregnant. USPSTF
Specialist nutrition consult for vegetarians/vegans. Purpose: secure B12 adequacy where intake may be low. Mechanism: fortified foods or B12 supplements. PMC
Occupational/environmental exposure review. Purpose: identify potential toxins/metals that may raise risk. Mechanism: mitigation and workplace safety. PMC
Family and community support networks. Purpose: reduce isolation and distress. Mechanism: coordinated multidisciplinary care and community resources. National Alliance for Care at Home
Drug treatments
For craniorachischisis there is no drug that treats or reverses the fetal condition. Medicines are used around the condition for prevention or maternal care. Below are 20 medication strategies relevant to prevention and counseling (not fetal cure).
Folic acid (standard dose). 0.4–0.8 mg daily for everyone who could become pregnant; start before conception and continue in early pregnancy. Lowers NTD risk. USPSTF
High-dose folic acid for high-risk. 4–5 mg daily preconception through 12 weeks for prior NTD, certain meds (e.g., valproate/carbamazepine), or strong risk per clinician. MGH Women’s Mental Health+1
Vitamin B12 supplementation. Typical preventive dosing ranges 250–500 mcg/day oral (or periodic injections) to correct deficiency and support folate pathways. PMC
Prenatal multivitamin with folate. Ensures consistent intake; many contain 0.4–0.8 mg folic acid. CDC
Switching from valproate when possible. Transition to lamotrigine or levetiracetam before pregnancy lowers teratogenic risk; specialist oversight required. JAMA Network
Optimizing diabetes meds. Tight glucose control (often with insulin) before and during early pregnancy reduces NTD risk tied to hyperglycemia. PMC
Prompt fever treatment (e.g., acetaminophen). Managing maternal fevers may help reduce hyperthermia-related risk (use per clinician advice). Lippincott Journals
Choline (adjunct in prenatal vitamins or diet). Aim for ~450 mg/day in pregnancy; supports one-carbon metabolism and neural development. PMC
Myo-inositol (research/recurrence settings). Investigational in folate-resistant NTD recurrence; discuss only in specialist care. PMC
Avoid known folate antagonists when possible. If a drug interferes with folate pathways, clinicians seek alternatives in early pregnancy. PMC
B12 injections for malabsorption. For pernicious anemia or gastric surgery, 1,000 mcg IM schedules ensure adequate stores pre-conception. PMC
Metformin/insulin titration per diabetes protocol. Keeps A1c in recommended range pre-conception. PMC
Folinic acid is not a substitute for folic acid prevention but may be used for certain antifolate exposures; counseling is individualized. PMC
Iodine in prenatal vitamins (for thyroid health; not NTD-specific) as part of overall neurodevelopment support. CDC
Iron (if deficient) to support maternal health; not NTD-specific but part of standard prenatal care. CDC
Antiemetics to allow women with severe nausea to keep down vitamins and food, preserving folate intake. PMC
B12 for vegans/vegetarians (oral daily or periodic injections) to reach >300 ng/L before conception. PMC
ASM therapeutic drug monitoring when switching meds pre-conception to stay seizure-free on safer options. JAMA Network
Avoid retinoids/isotretinoin in pregnancy (teratogenic); medication reconciliation prevents exposure. PMC
Peripartum analgesia and comfort meds for palliative births as part of family-centered care plans. National Alliance for Care at Home
Dietary molecular supplements
Only folic acid has proven population-level prevention impact. Others support overall one-carbon metabolism or maternal health; evidence quality varies.
Folic acid 400–800 mcg/day (core). Directly lowers NTD risk when started before conception. USPSTF
High-dose folic acid 4–5 mg/day (high-risk only). For recurrence prevention or certain meds, under clinician guidance. MGH Women’s Mental Health
Vitamin B12 (e.g., 250–500 mcg/day oral). Corrects deficiency associated with higher NTD risk. PMC
Choline (~450 mg/day in pregnancy). Supports neural development; low levels linked with higher NTD risk. PMC
Myo-inositol (research contexts). Potential adjunct for folate-resistant recurrences; discuss with specialists. PMC
Zinc (meet RDA via diet/supps if deficient). Experimental and limited human data suggest a role in closure. Avoid excess. PMC
Balanced prenatal multivitamin. Ensures broad micronutrient sufficiency supporting fetal development overall. CDC
Protein adequacy from food. Provides methionine for one-carbon cycles; part of overall diet quality. PMC
B-complex (including B6) to support homocysteine metabolism; not NTD-specific evidence but supports folate/B12 pathways. PMC
Dietary pattern rich in folate/B12/choline foods. Leafy greens, fortified grains, beans, eggs, dairy/meat (or fortified vegan alternatives). CDC
Immunity booster / regenerative / stem-cell drugs
There are no immune, regenerative, or stem-cell drugs that can repair or reverse craniorachischisis. Once early neural tube closure fails, the anatomy cannot be reconstructed. Ethical, palliative, and preventive care are the evidence-based approaches. Pediatric Ethicscope+1
Surgeries
Surgery can help in other NTDs like myelomeningocele (including prenatal repair), but not in craniorachischisis or anencephaly. Families are counseled toward comfort-focused plans. PMC+1
Prenatal myelomeningocele repair (MOMS trial) — not for craniorachischisis/anencephaly. PMC
Postnatal closure of spina bifida — applies to isolated myelomeningocele, not craniorachischisis. UCSF Fetal Treatment Center
Shunt for hydrocephalus — may help spina bifida survivors; not relevant in anencephaly. UCSF Fetal Treatment Center
Fetoscopic variants of MMC repair — research/centers of excellence; again not applicable here. Bjaed
Perinatal palliative procedures — comfort measures only (not curative). National Alliance for Care at Home
Prevention
Take 400–800 mcg folic acid daily if you could become pregnant. Start before pregnancy. USPSTF
If you had an NTD-affected pregnancy or take certain meds, use 4–5 mg folic acid with clinician guidance. MGH Women’s Mental Health
Review antiseizure meds with your neurologist before conception; avoid valproate if possible. JAMA Network
Control diabetes tightly before conception. PMC
Treat fevers early; avoid saunas/hot tubs in early pregnancy. Lippincott Journals
Eat a folate/B12/choline-rich diet and use a prenatal multivitamin. CDC+1
Aim for a healthy weight before pregnancy. PMC
Plan pregnancies when possible so folic acid is already on board. USPSTF
Avoid known teratogens (e.g., retinoids) and review all meds pre-conception. PMC
Seek early prenatal care and a first-trimester scan (11–14 weeks). PMC
When to see doctors
Before pregnancy: If you could become pregnant, see a clinician to start folic acid, review medications (especially anti-seizure drugs), and plan for diabetes/weight management. USPSTF+2JAMA Network+2
As soon as you’re pregnant (or think you are): Book early prenatal care and a first-trimester ultrasound. Continue vitamins. PMC
If you have fever early in pregnancy: Treat and call your clinician to reduce hyperthermia risk. Lippincott Journals
If an NTD is suspected/diagnosed: Ask for referral to maternal–fetal medicine, genetic counseling, neonatology, and perinatal palliative care to plan next steps that fit your values and local laws. PubMed+1
What to eat and what to avoid
Do eat folate-rich foods (leafy greens, beans, citrus) and folic-acid-fortified grains daily. Keep taking your folic-acid supplement. CDC
Do include B12 sources (fish, dairy, eggs, meat) or a B12 supplement if vegetarian/vegan. PMC
Do include choline sources (eggs, legumes, meats) or a prenatal with choline. PMC
Do maintain good hydration and balanced meals to support overall maternal health. CDC
Avoid overheating foods/activities that raise core body temperature (saunas/hot tubs) in early pregnancy. Lippincott Journals
Avoid alcohol and smoking (general fetal health).
Avoid unapproved supplements with unknown contents; stick to reputable prenatal vitamins. CDC
Be cautious with high-dose vitamin A (retinoids) and any prescription with teratogenic potential; review with your clinician. PMC
If you have nausea, ask for safe antiemetics so you can keep down folic acid and food. PMC
Watch B12 if plant-based. Use fortified foods or supplements to keep levels adequate before conception. PMC
FAQs
1) Can craniorachischisis be cured?
No. It is a lethal malformation; care focuses on early diagnosis, counseling, and palliative planning. PMC
2) Is it the same as anencephaly?
It includes anencephaly plus a long open spinal defect (rachischisis). Orpha
3) Can surgery fix it before birth?
No. Fetal surgery helps some myelomeningocele cases, not craniorachischisis/anencephaly. PMC
4) How early can it be seen?
Often at 11–14 weeks by experienced sonographers. PMC
5) What is the main prevention step?
Daily folic acid 400–800 mcg for all who could become pregnant, started before conception. USPSTF
6) What if I already had an NTD-affected pregnancy?
Use high-dose folic acid (usually 4–5 mg) in the next pregnancy (clinician-guided). MGH Women’s Mental Health
7) Do B12 or choline matter?
Low vitamin B12 and choline intakes are linked to higher NTD risk; ensure adequacy with diet/supplements. PMC+1
8) Are antiseizure medicines safe?
Some raise risk (especially valproate). Never stop on your own; work with your neurologist to choose safer options before conception. JAMA Network
9) Does fever increase risk?
Yes—hyperthermia in early pregnancy is a risk; treat fevers and avoid saunas/hot tubs. Lippincott Journals
10) What are my choices after diagnosis?
Depending on local law and values: termination or continuation with palliative care planning. Pediatric Ethicscope+1
11) What screenings detect open NTDs?
MSAFP at 16–18 weeks, detailed ultrasound, and sometimes AChE in amniotic fluid. The Lancet+1
12) What is the recurrence risk?
Higher than baseline after one affected pregnancy; high-dose folic acid reduces it. Your clinician can personalize numbers. USPSTF
13) Can inositol help?
It’s investigational for folate-resistant recurrent NTDs; discuss only in specialist settings. PMC
14) Do all countries fortify foods?
No. Where fortification is in place, NTD rates typically fall. Supplements still recommended for individuals. PMC
15) Why do we still see cases if folic acid works?
Because some NTDs are folate-resistant, and many pregnancies are unplanned, so supplementation starts too late. PMC+1
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 17, 2025.
Holoanencephaly
